Long noncoding RNAs (lncRNAs) have recently emerged as important players in diverse cellular processes. Among them, a large fraction of lncRNAs are localized within cell nucleus. And several of these nuclear-retained lncRNAs have been found to regulate key nuclear processes, which brings up the requirement of effective genetic tools to explore the functions of this “dark matter” inside the nucleus. While siRNAs and shRNAs are widely used tools in loss-of-function studies, their general efficiency in depleting nuclear-retained lncRNAs is limited, due to the fact that the RNAi machinery is located mainly in the cytoplasm of mammalian cells. Here, we describe the usage of chemically modified chimeric DNA antisense oligonucleotides (ASO) in effective knockdown of nuclear-retained lncRNAs, with a focus on the detailed workflow from the design and synthesis of ASOs, to in vitro and in vivo delivery methods.
Chemically modified chimeric DNA antisense oligonucleotides (ASO) Long noncoding RNAs (lncRNAs) Nuclear-retained long noncoding RNAs (nr-lncRNAs) Knockdown Lipid transfection Electroporation Free uptake In vivo delivery
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
Research in the KVP lab is supported by grants from NIH/NIGMS (GM088252) and American Cancer Society (RSG-11-174-01-RMC).
Singh DK, Prasanth KV (2013) Functional insights into the role of nuclear-retained long noncoding RNAs in gene expression control in mammalian cells. Chromosome Res 21(6–7):695–711PubMedCentralPubMedCrossRefGoogle Scholar
Nakagawa S, Kageyama Y (2014) Nuclear lncRNAs as epigenetic regulators-Beyond skepticism. Biochim Biophys Acta 1839(3):215–222Google Scholar
Tripathi V et al (2010) The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 39(6):925–938PubMedCentralPubMedCrossRefGoogle Scholar
Tripathi V et al (2013) Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet 9(3):e1003368PubMedCentralPubMedCrossRefGoogle Scholar
Gagnon KT, Li L, Chu Y, Janowski BA, Corey DR (2014) RNAi factors are present and active in human cell nuclei. Cell Rep 6(1):211–221PubMedCrossRefGoogle Scholar
Billy E, Brondani V, Zhang H, Muller U, Filipowicz W (2001) Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. Proc Natl Acad Sci U S A 98(25):14428–14433PubMedCentralPubMedCrossRefGoogle Scholar
Kawasaki H, Taira K (2003) Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res 31(2):700–707PubMedCentralPubMedCrossRefGoogle Scholar
Chiu YL, Ali A, Chu CY, Cao H, Rana TM (2004) Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 11(8):1165–1175PubMedCrossRefGoogle Scholar
Vickers TA et al (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 278(9):7108–7118PubMedCrossRefGoogle Scholar
Ideue T, Hino K, Kitao S, Yokoi T, Hirose T (2009) Efficient oligonucleotide-mediated degradation of nuclear noncoding RNAs in mammalian cultured cells. RNA 15(8):1578–1587PubMedCentralPubMedCrossRefGoogle Scholar
Lima WF et al (2007) Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol Pharmacol 71(1):83–91PubMedCrossRefGoogle Scholar
Koller E et al (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39(11):4795–4807PubMedCentralPubMedCrossRefGoogle Scholar
Graham MJ et al (2007) Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 48(4):763–767PubMedCrossRefGoogle Scholar
Hung G et al (2013) Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Therapeut 23(6):369–378CrossRefGoogle Scholar
Butler M et al (2005) Spinal distribution and metabolism of 2′-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats. Neuroscience 131(3):705–715PubMedCrossRefGoogle Scholar
Geary RS, Henry SP, Grillone LR (2002) Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 41(4):255–260PubMedCrossRefGoogle Scholar
Seth PP et al (2010) Synthesis and biophysical evaluation of 2′,4′-constrained 2′O-methoxyethyl and 2′,4′-constrained 2′O-ethyl nucleic acid analogues. J Org Chem 75(5):1569–1581PubMedCrossRefGoogle Scholar
Ostergaard ME et al (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41(21):9634–9650PubMedCentralPubMedCrossRefGoogle Scholar